The clinical development of new mitotic inhibitors that stabilize the microtubule

Sridhar Mani, Manuel Macapinlac, Sanjay Goel, Dominik Verdier-Pinard, Tito Fojo, Mace Rothenberg, Dimitrios Colevas

Research output: Contribution to journalReview articlepeer-review

75 Scopus citations


Microtubule-stabilizing agents are increasingly studied for cancer treatment based largely on the prior success of paclitaxel and docetaxel. In this review, we focus on the clinical development of epothilones and discodermolide, and we discuss salient preclinical and clinical highlights of these two novel natural products. These agents are distinguished by their biochemical features making them poor P-glycoprotein substrates and capable of inducing cytotoxicity in cell lines or in vivo tumor models harboring mutations in tubulin. There is now considerable data regarding the efficacy of the epothilones in human beings and discodermolide holds such promise, as well.

Original languageEnglish (US)
Pages (from-to)553-558
Number of pages6
JournalAnti-Cancer Drugs
Issue number6
StatePublished - Jul 1 2004


  • Discodermolide
  • Eluethrobin
  • Epothilones
  • Microtubule binding drugs
  • Taxanes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'The clinical development of new mitotic inhibitors that stabilize the microtubule'. Together they form a unique fingerprint.

Cite this